A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Gro... von OSENGA, Kaci L, HANK, Jacquelyn A, KRAILO, Mark, ADAMSON, Peter C, REISFELD, Ralph A, GILLIES, Stephen D, SONDEL, Paul M, ALBERTINI, Mark R, GAN, Jacek, STERNBERG, Adam G, EICKHOFF, Jens, SEEGER, Robert C, MATTHAY, Katherine K, REYNOLDS, C. Patrick, TWIST, Clare

Volltext

Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patients von KING, David M, ALBERTINI, Mark R, EICKHOFF, Jens, KENDRA, Kari, REISFELD, Ralph, GILLIES, Stephen D, SONDEL, Paul, SCHALCH, Heidi, HANK, Jacquelyn A, GAN, Jacek, SURFUS, Jean, MAHVI, David, SCHILLER, Joan H, WARNER, Thomas, KIM, Kyungmann

Volltext

Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma von Choi, Brian S, Sondel, Paul M, Hank, Jacquelyn A, Schalch, Heidi, Gan, Jacek, King, David M, Kendra, Kari, Mahvi, David, Lee, Li-Yin, Kim, Kyungmann, Albertini, Mark R

Volltext

Phase II trial of weekly paclitaxel in patients with advanced melanoma von Walker, Leslie, Schalch, Heidi, King, David M, Dietrich, Leah, Eastman, Michael, Kwak, Minjung, Kim, KyungMann, Albertini, Mark R

Volltext

Effective Particle-mediated Vaccination against Mouse Melanoma by Coadministration of Plasmid DNA Encoding Gp100 and Granulocyte-Macrophage Colony-Stimulating Factor von RAKHMILEVICH, Alexander L, IMBODEN, Michael, ZHENGLING HAO, MACKLIN, Michael D, ROBERTS, Timothy, WRIGHT, Kelly M, ALBERTINI, Mark R, YANG, Ning-Sun, SONDEL, Paul M

Volltext

Dermatomyositis after interferon alpha treatment von DIETRICH, L. L, BRIDGES, A. J, ALBERTINI, M. R

Volltext

Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients von ALBERTINI, M. R, HANK, J. A, SCHILLER, J. H, KHORSAND, M, BORCHERT, A. A, GAN, J, BECHHOFER, R, STORER, B, REISFELD, R. A, SONDEL, P. M

Volltext

Central venous device‐related infection and thrombosis in patients treated with moderate dose continuous‐infusion interleukin‐2 von Eastman, Michael E., Khorsand, Masoud, Maki, Dennis G., Williams, Eliot C., Kim, KyungMann, Sondel, Paul M., Schiller, Joan H., Albertini, Mark R.

Volltext

Dendritic cell-based immunotherapy for cancer and relevant challenges for transfusion medicine von Voss, Ching Y, Albertini, Mark R, Malter, James S

Volltext

Donor–derived small cell lung carcinoma in a kidney transplant recipient von Bodvarsson, Sigurdur, Burlingham, William, Kusaka, Satoshi, Hafez, Gholam‐Reza, Becker, Bryan N., Pintar, Thomas, Sollinger, Hans W., Albertini, Mark R.

Volltext

Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer von Hogge, G S, Burkholder, J K, Culp, J, Albertini, M R, Dubielzig, R R, Keller, E T, Yang, N S, MacEwen, E G

Volltext

Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogs von Hogge, G S, Burkholder, J K, Culp, J, Albertini, M R, Dubielzig, R R, Yang, N S, MacEwen, E G

Volltext

Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma von Mahvi, D M, Sondel, P M, Yang, N S, Albertini, M R, Schiller, J H, Hank, J, Heiner, J, Gan, J, Swain, W, Logrono, R

Volltext

Tumor growth, weight loss and cytokines in SCID mice von Murray, Susan, Schell, Kathleen, McCarthy, Donna O., Albertini, Mark R.

Volltext

Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors von SURFUS, J. E, HANK, J. A, OOSTERWIJK, E, WELT, S, LINDSTROM, M. J, ALBERTINI, M. R, SCHILLER, J. H, SONDEL, P. M

Volltext

Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study von Schiller, J H, Hank, J A, Khorsand, M, Storer, B, Borchert, A, Huseby-Moore, K, Burns, D, Wesly, O, Albertini, M R, Wilding, G, Sondel, P M

Volltext

Antigenicity of human melanoma cells transfected to express the B7-1 co-stimulatory molecule (CD80) varies with the level of B7-1 expression von MCCARTHY, D. O, GLOWACKI, N, SCHELL, K, EMLER, C. A, ALBERTINI, M. R

Volltext

B7.1 expression eliminates tumor resistance to IL-12 gene therapy von Heise, C P, Shi, F, Albertini, M R, Mahvi, D M

Volltext

Systemic interleukin-2 modulates the anti-idiotypic response to chimeric anti-GD2 antibody in patients with melanoma von ALBERTINI, M. R, GAN, J, SONDEL, P. M, JAEGER, P, HANK, J. A, STORER, B, SCHELL, K, RIVEST, J, SURFUS, J, REISFELD, R. A, SCHILLER, J. H

Volltext

Analysis of T cell receptor β and γ genes from peripheral blood, regional lymph node and tumor-infiltrating lymphocyte clones from melanoma patients von ALBERTINI, M. R, NICKLAS, J. A, CHASTENAY, B. F, HUNTER, T. C, ALBERTINI, R. J, CLARK, S. S, HANK, J. A, SONDEL, P. M

Volltext